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Background: Having the apolipoprotein E4 (APOE-ε4) allele is the strongest genetic risk factor for the development
of Alzheimer’s disease (AD). Accumulation of amyloid beta (Aβ) in the brain is influenced by APOE genotype. Transgenic
mice co-expressing five familial AD mutations (5xFAD) in the presence of human APOE alleles (ε2, ε3 or ε4) exhibit APOE
genotype-specific differences in early Aβ accumulation, suggesting an interaction between APOE and AD pathology.
Whether APOE genotype affects Aβ-plaque-associated neuroinflammation remains unclear. In the current study,
we address the role of APOE genotype on Aβ-associated microglial reactivity in the EFAD transgenic mouse
model.
Methods: We analyzed Aβ-induced glial activation in the brains of 6-month-old EFAD transgenic mice (E2FAD,
E3FAD and E4FAD). Region-specific morphological profiles of Aβ plaques in EFAD brain sections were compared
using immunofluorescence staining. We then determined the degree of glial activation in sites of Aβ deposition
while comparing levels of the inflammatory cytokine Interleukin-1β (IL-1β) by ELISA. Finally, we quantified parameters
of Aβ-associated microglial reactivity using double-stained EFAD brain sections.
Results: Characterization of Aβ plaques revealed there were larger and more intensely stained plaques in E4FAD
mice relative to E2FAD and E3FAD mice. E4FAD mice also had a greater percentage of compact plaques in the
subiculum than E3FAD mice. Reactive microglia and dystrophic astrocytes were prominent in EFAD brains, and
primarily localized to two sites of significant Aβ deposition: the subiculum and deep layers of the cortex. Cortical
levels of IL-1β were nearly twofold greater in E4FAD mice relative to E3FAD mice. To control for differences in
levels of Aβ in the different EFAD mice, we analyzed the microglia within domains of specific Aβ deposits.
Morphometric analyses revealed increased measures of microglial reactivity in E4FAD mice, including greater
dystrophy, increased fluorescence intensity and a higher density of reactive cells surrounding cortical plaques,
than in E3FAD mice.
Conclusions: In addition to altering morphological profiles of Aβ deposition, APOE genotype influences
Aβ-induced glial activation in the adult EFAD cortex. These data support a role for APOE in modulating
Aβ-induced neuroinflammatory responses in AD progression, and support the use of EFAD mice as a suitable
model for mechanistic studies of Aβ-associated neuroinflammation.
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Alzheimer’s disease (AD) is a progressive age-related
neurodegenerative disorder, which results in declarative
memory deficits and an impaired ability to function in
daily life [1,2]. It is the most common form of dementia
in the elderly and currently affects over 5 million people* Correspondence: gwr2@georgetown.edu
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unless otherwise stated.in the United States alone. Pathologically, it is charac-
terized by the presence of numerous amyloid plaques
and neurofibrillary tangles in the brain [3,4], with particu-
lar pathological effects appearing in the medial temporal
lobe and cortex. Extracellular plaques are formed by the
aggregation and deposition of amyloid beta (Aβ) peptides.
Aβ aggregates are associated with dystrophic astrocytes
and microglia as well as pro-inflammatory molecules
that may exacerbate AD pathology [5-7]. Indeed, theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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damage, stemming in part by Aβ-driven neuroinflamma-
tory responses [8,9].
Apolipoprotein E (APOE) is a polymorphic gene in
humans (APOE-ε2, APOE-ε3 APOE-ε4), coding for three
common protein isoforms that differ at positions 112 and
158 [10]. Although primarily associated with lipid and
cholesterol homeostasis in the central nervous system
(CNS) and periphery, APOE exerts genotype-specific
effects on Aβ aggregation, metabolism, and plaque load
in both AD patients and mouse models of AD [11-19].
Levels of Aβ found in the AD brain are strongly affected
by APOE genotype [20-22], contributing to its role as a
major genetic risk factor for AD [23-25]. Interestingly,
APOE genotype also differentially affects glial-mediated
inflammatory responses in the brain [22,26-30], suggesting
that APOE-associated AD risk may in part be driven by
dysfunctional neuroinflammation in response to Aβ
pathology. At present, the effects of APOE genotype
on Aβ-associated glial activation are unclear.
The EFAD transgenic mouse model was recently de-
veloped to investigate APOE-genotype-specific effects
on AD pathological changes in the brain [31,32]. In this
model, 5xFAD mice expressing transgenic forms of the
amyloid precursor protein (APP) and presenilin-1 (PS1)
[33] were crossed to APOE knock-in mice expressing each
of the three APOE isoforms [34]. The resulting EFAD
mice (E2FAD, E3FAD and E4FAD) exhibit robust amyloid
deposition in the brain, even at young ages [32]. Young
(2 to 6 month old) E4FAD mice exhibit accelerated Aβ
accumulation in the subiculum and frontal cortex, greater
total levels of Aβ1–42 in the hippocampus, and selective
increases in soluble Aβ42 and oligomeric Aβ (oAβ) com-
pared to E2FAD and E3FAD mice. Thus, EFAD transgenic
mice are a tractable model of APOE-influenced extracellu-
lar Aβ deposition in the brain, and may be an attractive
model for investigating the synergistic effects of APOE
genotype and plaque deposition on neuroinflamma-
tion. Whether APOE genotype differentially affects Aβ-
associated neuroinflammation in the brains of EFAD mice
has not been addressed.
Glial-mediated inflammatory responses to Aβ are an
important mechanism in AD pathogenesis, yet little is
known regarding the role of APOE genotype in this
process. In the current study, we examined the influence
of APOE genotype on Aβ plaques and plaque-associated
glial activation in 6-month-old EFAD mice using immu-
nohistochemistry. We report that APOE4 had an effect on
Aβ plaques in the brain, and that E4FAD mice exhibited
an increased density of reactive microglia within cortical
plaque domains, independent of overall plaque burden.
These data suggest that APOE genotype differentially
affects extracellular Aβ-associated microglial activation
in the brain.Material and methods
Animals
EFAD mice were used for all experiments and have been
described previously [32]. Briefly, EFAD mice co-express
five FAD mutations (APP K670N/M671L + I716V + V717I
and PS1 M1461L + L286V) on backgrounds of homozy-
gous APOE2, APOE3 or APOE4 knock-in genotypes. All
EFAD mice were on a C57BL/6 J genetic background
and were maintained in a temperature- and humidity-
controlled vivarium at the University of Illinois at Chicago,
provided food and water ad libitum, and subjected to a
standard 12-hr light/dark cycle. All experiments were con-
ducted in accordance with National Institutes of Health
guidelines for the care and use of laboratory animals, and
all protocols were reviewed and approved by the institu-
tional animal care and use committees at the University of
Illinois at Chicago.
Tissue harvesting
Brain tissue was harvested as previously described [32].
Briefly, 6-month-old EFAD mice (E2FAD, n = 4; E3FAD,
n = 5; E4FAD, n = 5) were deeply anesthetized with sodium
pentobarbital (50 mg/kg) and perfused transcardially with
ice-cold 100 mM phosphate-buffered saline (PBS) pH 7.4.
Brains were dissected at the midline, with the left hemi-
brains fixed in 4% paraformaldehyde for 48 hr, rinsed and
stored at 4°C in PBS plus 0.05% sodium azide until use.
Right hemi-brains were dissected on ice to give cortex,
hippocampus and cerebellum samples, then snap frozen
in liquid nitrogen, and finally stored at −80°C until use.
Biochemical analysis of IL-1β levels in the cortex
Serial extraction of soluble proteins was performed as
previously described [32]. Briefly, the dissected cortices
were homogenized in 15 volumes (w/v) of tris-buffered
saline (TBS), centrifuged (100,000 g, 1 hr at 4°C) and
the TBS-soluble extract was frozen in liquid nitrogen
and stored at −80°C. IL-1β levels were measured by
ELISA (Life Technologies, Carlsbad, CA) according to
the manufacturer’s instructions, and normalized to total
protein levels (Quick Start™ Bradford Assay, Bio-Rad,
Hercules, CA).
Tissue processing for immunohistochemical analysis
Sagittal brain sections (30 μm) were sliced in ice-cold
PBS using a Leica VT1000S vibratome and stored in cryo-
protectant at −20°C until the immunostaining procedures.
Sections processed for staining and analysis correspond
approximately to plates 111, 115 and 119 in the Paxinos
and Franklin mouse brain atlas [35], following a 1:9 series
of tissue staining. For both peroxidase and fluorescence
staining procedures, E2FAD, E3FAD and E4FAD brain
sections were processed in parallel.
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Cryoprotectant was washed from free-floating tissue
sections with PBS before quenching endogenous peroxi-
dases with 3% H2O2. Sections were then blocked with
3% BSA and 10% horse serum in PBS for 1 hr at room
temperature, followed by overnight incubation at 4°C with
either Iba1 (1:5,000) or GFAP (rabbit, 1:500 dilution of
0.4 μg/μL stock) (Invitrogen, Carlsbad, CA) antibodies
in blocking buffer. Tissue sections were rinsed and in-
cubated with a biotinylated secondary antibody (goat
anti-rabbit, 1:1,000 dilution of 1.5 mg/mL stock) (Vector
Labs, Burlingame, CA) for 1 hr at room temperature. Sec-
tions were then incubated with an avidin-biotin conjugate
(VECTA STAIN Elite ABC Kit, Vector Labs) before being
developed in PBS containing 0.04% 3,3'-diaminobenzidine
(DAB) hydrochloride and 0.04% nickel ammonium sulfate.
After staining was complete, sections were mounted on
glass Superfrost Plus slides, allowed to air dry for 24 hr,
then dehydrated and cleared with xylene before being
covered by a coverslip.
Immunofluorescence staining
Prior to immunofluorescence staining, free-floating tissue
sections were washed in TBS pH 7.4, then subjected to
heat-mediated antigen retrieval for 10 min in 30 mM
sodium citrate buffer (pH 6.0) containing 0.05% Tween
20. Sections were then permeabilized with 0.25% Triton
X-100 in TBS (TBST) and blocked with 5% BSA in
TBST for 1 hr at room temperature. Tissue sections
were subsequently incubated with an anti-Aβ antibody,
MOAB2 (mouse IgG2b, 1:1,000 dilution of 0.5 mg/ml
stock) [32,36], and either an anti-microglia antibody, Iba1
(rabbit IgG, 1:5,000 dilution of 0.5 μg/μL stock) (WAKO
Pure-Chemical Industries, Osaka, Japan), or an anti-
astrocyte antibody, GFAP (rabbit IgG, 1:1,000 of stock)
(Millipore, Billerica, MA), diluted in TBST containing
2% BSA overnight at 4°C. Next, sections were washed in
TBST, then incubated with Alexa fluorophore-conjugated
secondary antibodies (Invitrogen) diluted 1:1,000 in TBST
containing 2% BSA for 1 hr at room temperature. After
subsequent washing, tissue sections were mounted onto
glass Superfrost Plus slides (Fisher Scientific, Pittsburgh,
PA) using Fluoromount-G (Southern Biotech, Birmingham,
AL), a coverslip was added and the slides were stored in the
dark at 4°C until imaging.
Image analysis
Immunoperoxidase-stained EFAD brain tissue was an-
alyzed under bright field microscopy using an AxioPhot
upright microscope (Zeiss Microsystems, Inc., Oberkochen,
Germany). Digital images were acquired using an AxioCam
HRm camera connected to a Dell computer running
AxioVision 4.8.2 software (Zeiss Microsystems, Inc.).
Region-specific gliosis was observed and qualitativelyassessed in the subiculum and deep layers of the cortex by
an investigator blinded to APOE genotype. Dystrophic
astrocytes were readily identified by their large somas,
hypertrophic primary processes and intense GFAP-
immunoreactivity relative to astrocytes outside the subicu-
lum and deep layers of the cortex. Reactive microglia were
characterized by swollen cell bodies and intense Iba1-
immunoreactivity. In separate experiments, z-stacked
images of double-stained immunofluorescent EFAD brain
sections were acquired and processed into two-dimensional
projection images using a Zeiss 510LSM confocal micro-
scope and the LSM Image Browser (Zeiss Microsystems,
Inc.), respectively. Image files were then coded and analyzed
in the freely available open-source image-processing suite
Fiji by an investigator blinded to APOE genotype [37].
Morphological features of Aβ plaques and gliosis in
EFAD brains were analyzed within individual fluorescent
channels in Fiji and saved via the ROI Manager. Aβ
plaques were defined as MOAB2-positive areas of stained
tissue consisting of a single massed body at least 10 μm in
diameter. Individual plaques within the subiculum and
deep layers of the cortex were selected for analysis by
an investigator blinded to APOE genotype. Plaques
were traced to obtain the plaque area (μm2), fluores-
cence intensity (AU) and plaque type. Sampled plaques
were classified into three major categories based on a
previous report [32]: (a) diffuse, having no center and
weak MOAB2 staining with a wispy morphology; (b)
dense core, having an obvious center that stains brightly
with MOAB2, and having weakly stained fibrils surround-
ing the core and (c) compact, having a very brightly
stained core with no obvious MOAB2 stained fibrils, and
generally smaller than other plaques (approximately 10 to
20 μm in diameter). Investigators sampled as many pla-
ques as possible in an image window for analysis, resulting
in over 200 plaques traced per APOE genotype. To obtain
morphological measures of Aβ-associated microgliosis,
75-μm-diameter rings were centered over plaques to de-
fine plaque domains and then superimposed on images of
Iba1-stained microglia. Plaques with little to no overlap-
ping plaque domains were randomly selected under the
same blinded conditions as plaque analysis, as was image
analysis of microgliosis. Total Aβ-associated microglial
density was calculated within each plaque domain, with a
distinct cell soma required for cell counts. Iba1 fluores-
cence intensities were also calculated within each plaque
domain. For each fluorescence channel, three measures of
background fluorescence were collected and the average
subtracted from the total fluorescence of individual
plaques and plaque domains in each image.
Additionally, the extent of Aβ-associated microglio-
sis in EFAD sections were analyzed by thresholding the
images and measuring the total area (μm2) occupied by
Iba1-stained microglial cell bodies and processes within
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8-bit single-channel images of Iba1 staining were adjusted
interactively (range 35 to 45) under blinded conditions
in Fiji using an over/under display mode (blue is back-
ground). The aggregate Iba1 immunoreactivity above
threshold was then measured within the superimposed
plaque domains and saved as a percentage of total plaque
domain area.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism 5 unless noted otherwise. Differences between means
were assessed by one-way analysis of variance (ANOVA),
or two-way ANOVA followed by Tukey’s honest significant
difference and Bonferroni post hoc tests, where appropriate.
Descriptive statistics are expressed as mean ± standard
error of the mean, with significance set at P < 0.05.
Results
APOE genotype affects Aβ plaque morphology in the
EFAD subiculum and deep layers of the cortex
5xFAD-Tg mice exhibit a region-specific accumulation
of Aβ in the brain as early as two months of age, with
significant levels of thioflavin-S-stained plaques appearing
in the hippocampus and cortex at four months [38].
Human APOE delays somewhat the formation of amyl-
oid plaques in these mice and decreases total levels of
Aβ1–42, and thus these mice are a tractable model for
studying the effects of APOE genotype on Aβ deposition
and Aβ-associated neuroinflammation [32]. To investigate
this area, we performed experiments by staining for Aβ
and microglia on tissue sections from 6-month-old EFAD
mice (E2FAD, n = 4; E3FAD, n = 5; E4FAD, n = 5). Initially,
we focused on assessing the region-specific Aβ deposition
in these sections by measuring Aβ (MOAB2) immunore-
activity. We quantified the following parameters from se-
lected individual Aβ-positive deposits in the subiculum
and deep layers of the cortex: plaque area, fluorescence
intensity and plaque type.
In the subiculum, we found a significant effect of APOE
genotype on plaque size (F(2,11) = 4.30, P < 0.05), with post
hoc comparisons revealing significantly larger plaques
sampled in E4FAD sections compared to E2FAD sections
(P < 0.05) (Figure 1B, left). MOAB2 fluorescence intensity
was not affected by APOE genotype (F(2,11) = 3.25,
P = 0.078) in this brain region (Figure 1B, center). Finally,
we defined Aβ deposits as diffuse, dense core or
compact plaques, expressed the total number of diffuse,
dense core and compact plaques as a percentage of total
plaques, and compared them within and between
APOE genotypes (Figure 1A and 1B right). Two-way
ANOVA revealed a significant main effect of plaque
type (F(2,33) = 26.65, P < 0.001) on the distribution of pla-
ques in all EFAD groups, with a greater number of densecore plaques (45.83 ± 0.3%) in the subiculum than diffuse
plaques (32.9 ± 0.5%) or compact plaques (21.10 ± 0.5%).
There was a higher percentage of diffuse plaques in
E2FAD sections compared to E3FAD sections (P < 0.05)
(E2FAD vs E3FAD; 45.0 ± 3.8% vs 28.3 ± 2.8%) and E4FAD
sections (25.5 ± 3.5%) (P < 0.01) (Figure 1B, right). There
were also significantly fewer dense core plaques in E2FAD
sections (33.9 ± 2.6%) than E3FAD sections (57.6 ± 2.8%)
(P < 0.01), and a higher percentage of compact plaques in
E4FAD sections (28.5 ± 4.8%) than E3FAD sections
(13.9 ± 1.1%) (P < 0.05). Thus, in the subiculum, APOE2
was associated with more diffuse plaques, and APOE4
with more compact plaques, compared to APOE3.
Within the deep layers of the cortex, we did not de-
tect EFAD group differences in plaque size (F(2,11) = 3.45,
P = 0.068) (Figure 1C, left). However, APOE genotype
did affect MOAB2 fluorescence intensity (F(2,11) = 4.88,
P < 0.05), with E4FAD plaques exhibiting higher MOAB2
positive staining compared to E3FAD plaques (P < 0.05)
(Figure 1C, center). A two-way ANOVA to assess the dis-
tribution of plaque types in the cortex revealed a signifi-
cant main effect of plaque type (F(2,33) = 21.43, P < 0.001)
for each EFAD group, with higher percentages of diffuse
plaques (42.7 ± 5.0%) and dense core plaques (35.8 ± 3.7%)
in EFAD sections than compact plaques (21.7 ± 1.9%)
(Figure 1C, right). Interestingly, a higher percentage of dif-
fuse plaques was again seen in E2FAD sections (50.8 ±
3.6%) compared to E4FAD sections (33.6 ± 5.0%).
These data identify two sites of robust extracellular Aβ
deposition in the brains of 6-month-old EFAD mice.
APOE genotype had an effect on plaque characteristics in
both the subiculum and deep layers of the cortex, which is
consistent with previous findings for these mice [32].
Glial activation is increased in the EFAD subiculum and
cortex, while E4FAD mice exhibit elevated IL-1β levels
Aβ accumulation and deposition in the brain can lead to
reactive gliosis [39]. This term refers to the physiological
activation of glial cells in response to focal tissue damage,
and is characterized by specific structural and functional
changes to glial cells that mediate the neuroinflammatory
response. Astrocytes and microglia are two important glial
cell types involved in Aβ-associated glial activation [40].
Therefore, we assessed glial activation in 6-month-old
EFAD mice by analyzing the distribution and numbers of
dystrophic astrocytes and microglial cells in the brain.
DAB-immunoperoxidase staining for GFAP (astrocytes)
was performed on sagittal brain sections from E2FAD,
E3FAD and E4FAD mice. Intense GFAP staining was evi-
dent in the subiculum of all EFAD mice (Figure 2A), with
numerous reactive astrocytes having dystrophic processes
in the region (Figure 2A, inset). Sparse, but intense, GFAP
staining was also evident in deep layers of the cortex,
where clusters of reactive astrocytes were detected
Figure 1 APOE genotype affects Aβ plaque morphology in EFAD subiculum and deep layers of cortex. Morphologically distinct Aβ
plaques were visualized in the subiculum and deep layers of the cortex of 6-month-old EFAD mice using immunofluorescence staining with
Aβ antibody MOAB2. (A) Heterogeneous plaque types were evident in EFAD brains and grouped into three categories: diffuse, dense core
and compact. Scale bar: 12 μm. (B) Subiculum. Left: E4FAD mice exhibited larger plaques on average than E3FAD mice. Center: Fluorescence
intensity of plaques did not differ by APOE genotype. Right: E2FAD mice exhibited a greater percentage of diffuse plaques than E3FAD or
E4FAD mice, and a lower percentage of dense core plaques than E3FAD mice. Interestingly, E4FAD mice exhibited an increased percentage
of compact plaques in the subiculum. (C) Deep layers of the cortex. Left: Plaque size did not differ by APOE genotype. Center: Fluorescence
intensity of deep cortical plaques was highest in E4FAD mice. Right: E2FAD mice had a greater percentage of diffuse plaques in this region
than E4FAD mice. No differences were detected between APOE genotype for dense core or compact plaques. One-way ANOVA, * P < 0.05.
Two-way ANOVA, * P < 0.05, ** P < 0.01.
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cence staining for GFAP and MOAB2 confirmed that
plaques were at the center of reactive astrocytic clusters in
deep cortical layers (data not shown). DAB staining
for Iba1 revealed a similar pattern for microglia in the
EFAD subiculum, although reactive microglia appeared
more frequent in the E4FAD and E2FAD cortices than
E3FAD cortices (Figure 2B, green arrows). Doubleimmunofluorescence staining for reactive astrocytes
and microglia was performed on adjacent EFAD sections
to visualize reactive gliosis in these regions. Dystrophic
astrocytes and microglial reactivity were clearly evident
in the subiculum, with both glial cell types exhibiting
strong intensity and activated morphologies (Figure 2C).
IL-1β is a member of the interleukin-1 family of cyto-
kines and is an important microglia-derived mediator of
Figure 2 Glial activation is increased in the EFAD subiculum and cortex, while E4FAD mice exhibit elevated IL-1β levels. Astrocytes and
microglia were visualized in sagittal brain sections of 6-month-old EFAD mice using immunohistochemistry. Initial DAB staining revealed
prominent gliosis in two regions of the brain: the subiculum and deep layers of the cortex. (A) Extensive GFAP-immunoperoxidase staining
was evident in the subiculum of all EFAD mice. In addition, dystrophic astrocytes could be seen throughout the deep layers, but not in
superficial layers, of the EFAD cortex. Insets: 20× magnification of the subiculum (dashed red box). Magenta arrows: Clusters of dystrophic
astrocytes in the cortex. Scale bar: 500 μm. (B) Activated microglial cells were clearly visible in the subiculum of all EFAD mice and were
present in deep cortical layers as well. E4FAD sections exhibited more activated microglia in the deep cortex than E2FAD and E3FAD sections. Green
arrows: Activated microglia. Scale bar: 500 μm. (C) Double immunofluorescence staining for GFAP (magenta) and Iba1 (green) confirmed region-specific
glial activation in EFAD brains. Representative images of EFAD subicula are shown. Scale bar: 30 μm. (D) Levels of the pro-inflammatory cytokine IL-1β were
measured using ELISA in 6-month-old EFAD cortex (CTX) extracts. E4FAD sections exhibited significantly higher levels of IL-1β than E3FAD sections.
One-way ANOVA, ** P< 0.01.
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significant activation of IL-1β in the brain, suggestive of
an Aβ-dependent neuroinflammatory response [41]. APOE
genotype exerts an influence over inflammatory re-
sponses in the brain independent of AD pathology [42].
APOE4 is associated with upregulated gene expression
of pro-inflammatory cytokines following traumatic brain
injury and lipopolysaccharide (LPS) treatment comparedto APOE3 [30,43]. To test whether APOE genotype affects
functional aspects of glial activation in EFAD mice, we
measured levels of the pro-inflammatory cytokine IL-1β
in TBS-soluble fractions of 6-month-old EFAD cortices
(E2FAD, n = 4; E3FAD, n = 4; E4FAD, n = 4) (Figure 2D).
One-way ANOVA revealed a significant effect of APOE
genotype (F(2,9) = 12.66, P < 0.01) on IL-1β levels. A signifi-
cant elevation in IL-1β was detected in the E4FAD cortex
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fold compared to E3FAD samples (23. 8 ± 1.5 pg/mg) and
E2FAD samples (26.0 ± 4.1 pg/mg).
Thus, morphological characteristics of reactive gliosis
were revealed in the adult EFAD subiculum and deep layers
of the cortex. Initial DAB-immunoperoxidase staining
showed strong glial immunoreactivity in the subiculum of
all mice. Increased clusters of astrocytes and an increased
number of reactive microglial cells were found in deep
layers of the E4FAD cortex compared to the E3FAD cor-
tex. Z-series projections of double-stained images revealed
highly dystrophic astrocytic and microglial processes. In
addition, we found elevated levels of pro-inflammatory
IL-1β in the E4FAD cortex.
E4FAD mice exhibit increased Aβ-associated microglial
reactivity in deep layers of the cortex
Our region-specific glial staining and ELISA data revealed
increased microglial reactivity in the E4FAD mouse brain.
To determine whether APOE genotype had an effect on
Aβ-associated microglial reactivity independent of plaque
load [32], we analyzed microglial activation within the
vicinity of individual Aβ plaques. Using the MOAB2/Iba1
double-stained tissue sections (Figures 1 and 3A,B,C), we
established domains around select plaques having little toFigure 3 Confocal microscopy analysis of Aβ-associated microglial ac
mice were analyzed for Aβ deposition and associated microglial activation
Reactive microglial cells within the vicinity of Aβ plaques consistently exhibited
projection image (approximately 20 μm, z-axis) of a E3FAD subiculum double s
depict metrics used to characterize and quantify Aβ deposition and assoc
(B) Grayscale image of Aβ plaques chosen for analysis. Plaque types, size of p
Traced plaques. (C) Grayscale image of activated microglia with plaque doma
were collected and quantified along with Iba1 fluorescence intensity. Yellow r
plaque domains to quantify the percentage area occupied by microglia cell b
(0 to 255 brightness scale) depicted. Blue: Background. Scale bars: 20 μm.no overlap with other domains (Figure 3A,C). We then
isolated the Iba1-positive fluorescence images from the
original double-stained sets, superimposed plaque do-
mains on these single-channel images, and quantified
the following parameters within the plaque domains:
average number of microglial cells, Iba1 fluorescence
intensity and percentage area occupied by the microglia
(Figure 3C,D).
Representative images of Aβ-associated microglial
reactivity are shown for E2FAD, E3FAD, and E4FAD
subiculum (Figure 4A). Within this region of the EFAD
brain, we did not detect differences in the average number
of microglial cells surrounding plaques (F(2,11) = 2.64,
P > 0.05), Iba1-positive fluorescence intensity (F(2,11) = 0.54,
P > 0.05) or percentage area of plaque domain occupied by
microglia (F(2,11) = 0.64, P > 0.05) (Figure 4B).
However, in the deep layers of the cortex, activated
microglial profiles were elevated in E4FAD sections
compared to E3FAD sections (Figure 5A). We found a
significant effect of APOE genotype on the average num-
ber of microglial cells surrounding plaques (F(2,11) = 7.90,
P < 0.01), with E4FAD mice exhibiting a 2.3-fold increase
compared to E3FAD mice (P < 0.01) (Figure 5B, left).
Interestingly, Aβ-associated microglial cell counts were
also elevated within E2FAD plaque domains comparedtivation in EFAD mice. Sagittal brain sections from 6-month-old EFAD
in two regions of interest, the subiculum and deep layers of the cortex.
an amoeboid-like shape with dystrophic processes. (A) Two-dimensional
tained for Aβ1–42 (MOAB2) and activated microglia (Iba1). Image overlays
iated microglial activation. White arrows: Examples of plaque domains.
laques and MOAB2 fluorescence intensity were quantified. Magenta:
in overlays. The number of microglia cell bodies within plaque domains
ing: Plaque domains (4.42 mm2). (D) Thresholding was performed within
odies and processes. Representative minimum threshold value of 35
Figure 4 Aβ deposition in the subiculum is associated with high levels of microglial reactivity. Double immunofluorescence staining
of 6-month-old EFAD subicula revealed significant Aβ deposition and elevated microglial activation in each group. (A) Representative
images of fluorescence staining in EFAD subiculum. Aβ-associated microglial activation was assessed for each APOE genotype (n = 4 or 5
mice/APOE genotype). Scale bar: 30 μm. (B) Microglial density, fluorescence intensity and percentage area of the plaque domain did not
differ between APOE genotypes. Within the subiculum, the reactive microglia in each group occupies a large percentage of the plaque
domains relative to the deep cortex.
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ences in Aβ-associated microglia intensity (F(2,11) = 4.36,
P < 0.05) were detected between EFAD groups, with
increased staining intensity present in E4FAD plaque
domains relative to E3FAD plaque domains (P < 0.05)
(Figure 5B, center). When measuring the percentage area
of plaque domains occupied by microglia, we found a sig-
nificant effect of APOE genotype (F(2,11) = 7.35, P < 0.01)
(Figure 5B, right). Post hoc tests revealed a higher percent-
age of dystrophic microglia occupying E4FAD plaque do-
mains than E3FAD plaque domains (P < 0.01). The E2FAD
and E3FAD sections analyzed had similar percentages of
total microglial staining within plaque domains (E2FAD,
20.0 ± 1.2% vs E3FAD, 16.9 ± 0.8%), despite E2FAD plaque
domains containing more microglial cells than E3FAD
plaque domains (Figure 5B, left).
With this detailed analysis of EFAD brains, we found
that Aβ-associated microglia reactivity was not affected
by APOE genotype in the subiculum. However, we found
that APOE genotype affected morphological character-
istics of microglial reactivity, with several measures of
increased microglial activity detected within E4FAD
cortical plaque domains, independent of overall plaque
load.Discussion
APOE-dependent differences in the innate inflammatory
response to Aβ may partially explain the differential risk
for AD caused by APOE genotype [22]. In the present
study, we investigated whether APOE alleles affect glial
markers of Aβ-associated neuroinflammation in a mouse
model of Aβ deposition. First, we found that E4FAD
mice exhibited larger, more intensely stained Aβ plaques in
the brain compared to E2FAD and E3FAD mice. E4FAD
mice also had a greater number of compact plaques in the
subiculum than E3FAD mice. Initial immunostaining ex-
periments revealed activated astrocytes and microglial
cells in the subiculum and deep layers of the cortex, and
an ELISA revealed significantly elevated levels of IL-1β
in the E4FAD cortex. These findings prompted our inves-
tigation into microglial reactivity surrounding plaques in
the subiculum and deep cortex. We did not detect APOE-
dependent differences in microglial reactivity within the
subiculum, perhaps related to the very intense deposition
of Aβ in the region for all groups. In the deep layers of the
cortex, however, APOE genotype had a significant effect on
Aβ-associated microglial activation. E4FAD mice exhibited
higher numbers of reactive microglial cells surrounding
Aβ plaques and increased signs of activation compared to
Figure 5 APOE4 is associated with increased microglial reactivity to Aβ in deep layers of the cortex. Morphological profiles of reactive
microglia within deep cortical Aβ plaque domains were elevated in E4FAD mice. (A) Representative double-stained images of Aβ plaques and
microglial activation in deep layers of EFAD cortices (n = 4 or 5 mice/APOE genotype). Scale bar: 30 μm. (B) Left: E4FAD and E2FAD mice
exhibited increased reactive microglial density within Aβ plaque domains. Center: Fluorescence intensity of the microglia was elevated in
E4FAD mice relative to E3FAD mice. Right: E4FAD microglia occupied a larger percentage of plaque domains than E3FAD microglia.
One-way ANOVA, * P < 0.05, ** P < 0.01.
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associated microglial activation, an important component
of the neuroinflammatory response in AD, is augmented
by the APOE4 genotype.
5xFAD mice exhibit rapid amyloid deposition and
pathology in the brain. Extracellular amyloid can be
detected as early as 2 to 4 months of age in the subiculum
and deep layers of the cortex [32,33]. By introducing
human APOE alleles into the 5xFAD model, the effects
of APOE on amyloid-associated pathological changes in
the adult brain can be investigated. The EFAD mouse
model is particularly good for examining the effects of
APOE genotype on Aβ-associated inflammation. In our
experiments, we were first interested in characterizing
extracellular Aβ plaques in the brains of adult EFAD mice.
We found mostly large Aβ plaques in the E4FAD subi-
culum, with no group differences in MOAB2 staining
intensity (Figure 1B). Our morphological results support
findings showing a higher percentage of compact plaques
in the subiculum of 6-month-old E4FAD mice compared
to E3FAD mice (Figure 1B) [32]. We also found a higher
percentage of diffuse plaques in the subiculum of E2FAD
mice compared to E3FAD mice, though no differences
were found between these two groups previously [32].
This is likely due to the antibody used to stain plaquedeposits. Here we used MOAB2, a pan-specific Aβ anti-
body that recognizes several conformational species of
Aβ1–42 [36], while the previous study [32] used thioflavin-S
to stain beta-sheet-rich amyloid fibrils in plaques.
MOAB2-stained Aβ plaques were clear and could easily
be distinguished from one another using our methods
(Figure 1A). Importantly, the percentage of diffuse plaques
in the E2FAD subiculum was greater than in the E4FAD
subiculum, which supports previous plaque morphology
data for these mice [32]. In deep layers of the cortex,
APOE genotype did not influence plaque size, though we
did detect increased MOAB2-staining intensity in E4FAD
plaques compared to E3FAD plaques (Figure 1C). The
significance of greater plaque fluorescence intensity on
glial activation is unclear, but may be related to changes
in microglial reactivity surrounding plaques that we ob-
served in our studies. More research on Aβ deposition
and plaque-associated neuroinflammation in the EFAD
model is needed, with an emphasis on microglial-secreted
pro-inflammatory and anti-inflammatory signaling mole-
cules that affect nearby cells.
Microglial cells are the resident macrophages in the
CNS and are responsible for several functions of the innate
immune response [44,45]. Notably, the microglia survey
the brain parenchyma for foreign substances and cellular
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the material and clear the microenvironment. In our
experiments, both DAB-immunoperoxidase and double
immunofluorescence staining revealed aggressive astrocy-
tosis and microgliosis in the subiculum of E2FAD, E3FAD
and E4FAD mice (Figure 2A,C), while reactive microglia
were most visible in the cortex of E4FAD and E2FAD
mice (Figure 2B). Age-matched cortical samples were
analyzed for total IL-1β levels by ELISA. We detected
increased levels of pro-inflammatory IL-1β in the E4FAD
cortex compared to the E3FAD cortex (Figure 2D). These
data led us to investigate morphological markers of micro-
glial reactivity proximal to Aβ plaques in both brain re-
gions. Reactive microglia in AD brains have been found to
be localized to Aβ plaques [6,46], and in vitro studies have
shown that Aβ directly activates the microglia to produce
IL-1β, reactive oxygen species and tumor necrosis factor
α [47-49]. Interestingly, APOE is associated with Aβ-
independent immunomodulatory functions in vitro. ApoE
suppresses the LPS-stimulated release of tumor necrosis
factor α in primary glial cultures, and attenuates microglial
activation by secreting derivatives of amyloid precursor
protein in an isoform-dependent manner [50,51]. The
anti-inflammatory effects of APOE may be mediated
through low-density lipoprotein receptor-related protein
(LRP1) on microglia and subsequent suppression of the
c-Jun N-terminal kinase pathway [52,53]. In animal models,
apoE deficiency is associated with poor recovery from
CNS injuries involving neuroinflammation, demonstrating
its important immunomodulatory role in the brain
[54,55]. Our experiments using the EFAD model of Aβ
deposition have provided additional insights on the role
APOE plays in the neuroinflammatory response to AD
pathological brain changes.
Analyzing morphological markers of microglial activa-
tion within defined Aβ domains allowed us to control for
the effects of APOE on amyloid accumulation. Since
APOE4 is associated with higher levels of amyloid depos-
ition in both humans and mouse models, higher levels of
global inflammation would be expected for mice with
APOE4. In our analysis, we measured microglial reactivity
within the microenvironment of randomly selected Aβ
plaques (Figure 3). To fit our selection criteria, plaques
needed to be clearly visible, larger than 10 μm in diameter
and easily discerned from other plaque types. Every effort
was made to select individual plaques for analysis that
were at least 35 μm from another plaque, which we
determined was the maximum distance for which we
could accurately judge plaque-specific microglia reactivity.
This analysis proved challenging in the subiculum, where
each EFAD group exhibited aggressive Aβ deposition, and
thus plaques were more likely to be near one another. Our
results describing Aβ-associated microglia reactivity in the
subiculum may reflect this, as we did not detect APOEgenotype differences in Aβ-associated microglia reactivity
(Figure 4). We hypothesize that measuring Aβ-associated
microglial reactivity in the subiculum of younger EFAD
mice would remove the effects of proximal Aβ plaques,
as Aβ deposition would be reduced in the region and
more accurate assessments of glial activation could be
made. Nonetheless, we were able to measure markers of
microglia reactivity readily within the microenvironment
of plaques found in the deep layers of the cortex (Figure 5).
We detected an increased density of reactive intensely
stained microglia surrounding individual plaques in E4FAD
sections compared to E3FAD sections. Interestingly,
E2FAD mice also exhibited increased numbers of micro-
glial cells surrounding plaques, though these cells did not
appear as activated as those from E4FAD mice. This con-
clusion is reflected in the low Iba1 fluorescence intensity
and a smaller percentage area of the plaque domain occu-
pied by cell soma and processes. Thus, the higher domain
area occupied by the microglia in E4FAD mice likely re-
flects swollen cell somas and hypertrophic processes, and
not simply an increase in microglia density (Figure 5B).
Collectively, these data suggest that APOE genotype
differentially affects activation of microglia in response
to Aβ deposits, and that morphological profiles of micro-
glial reactivity can serve as a useful measure of Aβ-driven
neuroinflammation.
The effects of APOE genotype on the increased micro-
glial activation in E4FAD mice may be due to differences
in the form of apoE or in the amount of apoE. Several
studies have reported lower levels of total apoE in the
brains of APOE4 knock-in mice [56-58]. We previously
measured brain apoE levels in EFAD mice using a three-
step sequential protein extraction protocol (using TBS,
TBS-Triton X-100 and formic acid) [32]. Levels of apoE4
were selectively lower than apoE3 in the TBS-Triton
X-100 fraction, suggesting that the lower levels of apoE4
may be due to the fact that the apoE is less lipidated.
Lower levels of properly lipidated apoE could lead to less
receptor binding and attenuated inhibition of microglial
activation at Aβ plaques [52,53]. We previously found that
APOE knock-out and APOE4 knock-in mice have higher
levels of LPS-induced neuroinflammation and impaired
synaptic viability than APOE3 mice, suggesting that
the loss of apoE contributes to increased neuroinflamma-
tion [30]. These data are consistent with in vitro and
in vivo data showing that Aβ-independent neuroinflam-
mation is higher with APOE4 than APOE3 [26,58,59]. For
a review, see [60].
The type and amount of apoE also can affect glial re-
sponses to other forms of Aβ, in addition to extracellular
deposits. Our previous data demonstrate that levels of
soluble Aβ42 and soluble oAβ are higher in both the
hippocampus and cortex of E4FAD mice compared to
E3FAD mice [32]. Analysis of EFAD mice suggested that
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apoE4/Aβ complex, resulting in increased levels of soluble
oAβ [31,61]. However, dissecting the effect of APOE-
genotype-modulated extracellular Aβ vs soluble oAβ on
microglial activation in vivo is complex, as soluble Aβ and
insoluble Aβ exist in a dynamic compartmentalization
[62], and oAβ levels are higher in microenvironments sur-
rounding amyloid plaques [63]. Thus, both forms of Aβ
likely contribute to microglial activation. Collectively,
these data support the hypothesis that lipid-poor apoE4
may result in a loss of function not only on Aβ clearance,
but also on Aβ-independent and Aβ-driven neuroinflam-
mation, both of which are a focus of our ongoing studies.
In summary, we have shown that APOE genotype differ-
entially impacted Aβ-plaque-associated microglial activa-
tion in the brains of EFAD mice. APOE4 increased levels
of IL-1β and negatively affected morphological profiles of
microglial reactivity within cortical Aβ plaque domains. In
addition, APOE genotype affected characteristics of Aβ
plaques in the EFAD subiculum, supporting previously
reported data describing Aβ deposition in this model.
Our data support the use of the EFAD transgenic mouse
model for studies of Aβ-associated neuroinflammation,
and demonstrate the need for APOE-targeted therapeu-
tics in AD aimed at regulating neuroinflammation.
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